Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

NIAID News Release

Discovery Lays Groundwork for Potential New Class of Anti-HIV Drugs

March 31, 2003

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Researchers supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) have identified compounds that in the laboratory interfere with the assembly of HIV. This discovery lays the groundwork for development of a potential new class of drugs -- so-called assembly inhibitors -- to treat people with HIV/AIDS. Details of the work appear today in the online version of the Journal of Molecular Biology at www.sciencedirect.com/science/journal/00222836.

Michael F. Summers, Ph.D., a Howard Hughes Medical Institute investigator and professor of biochemistry at the University of Maryland, Baltimore County, led a team of undergraduate and graduate students in the effort. "This work is yet another pivotal achievement on the part of Dr. Summers and his students," says Anthony S. Fauci, M.D., NIAID director. "The fact that undergraduate students played important roles in this research makes it even more impressive." Dr. Summers and his student team have also successfully solved the structures of three important HIV proteins and several other components of HIV.

Although the current combination of reverse transcriptase inhibitors and protease inhibitors used against HIV can effectively lower a patient's viral load, lack of compliance and interactions with other drugs or diet can weaken the effect of these drug "cocktails," allowing resistant strains of HIV to emerge, Dr. Summers explains. Adding a new class of anti-HIV drugs such as assembly inhibitors to the mix may help solve this problem.

The recently identified compounds bind to HIV-1 capsid proteins and prevent these molecular building blocks from assembling into the HIV capsid, a cone-shaped inner structure of the virus that houses viral RNA, enzymes and other key viral components. Although the compounds do not stop new viruses from assembling, they cause viruses to form with defective capsids, and these abnormal viruses can not infect new cells. One compound in particular, CAP-1, is well-tolerated by human cells.

Advertisement
Using powerful computers, Dr. Summers' team screened hundreds of thousands of compounds, searching for those that might bind to the capsid protein. When the computer search generated a short list of "hits," the researchers then used a nuclear magnetic resonance machine to determine exactly where these compounds attached to the capsid protein. Although the compounds attached to a different area of the protein than the one the team originally expected, experiments with the live virus and human cells showed the compounds rendered HIV non-infectious.

Dr. Summers cautions that these compounds must be tested much more extensively before an experimental assembly inhibitor could be developed for clinical trials. "There is still a lot of chemistry to be done," Dr. Summers says. "We still have to work to determine the best compounds and test their toxicity in animals. But what is really exciting is that at least now there is a clear path to follow for this new class of inhibitors."

Collaborators in this effort include the Oregon Health and Science University in Portland and Achillion Pharmaceuticals of New Haven, CT, which conducted the live HIV virus experiments. In addition to funding from NIAID, Dr. Summers and his team received support from the National Institute of General Medical Sciences.


Reference

  1. C. Tang et al. Antiviral Inhibition of the HIV-1 Capsid Protein. Journal of Molecular Biology 327(5):1013-20 (2003). Published online at www.sciencedirect.com/science/journal/00222836.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
More on HIV Medications
Drugs in Development: Other New Drugs

Tools
 

Advertisement